Entabor2 is Niihara International’s pharmaceutical-grade L-glutamine formulation developed for clinical use, particularly in patients with sickle cell disease.
Unlike food-grade or supplement-grade glutamine products, Entabor2 is designed to meet pharmaceutical standards for purity, consistency, and clinical reliability.
Sickle cell disease is driven in part by oxidative damage to red blood cells, which contributes to cell rigidity, hemolysis, and vascular blockage.
L-glutamine therapy works by:
This mechanism was first identified through research conducted by Drs. Zerez and Niihara at Harbor-UCLA Medical Center.
Clinical trials and follow-up studies have shown that L-glutamine therapy can produce substantial and durable benefits, including:
These outcomes translate directly into fewer emergency interventions, lower healthcare costs, and improved quality of life for patients and families.
Beyond sickle cell disease, pharmaceutical-grade L-glutamine has been studied for its role in:
Gastrointestinal health
Including reduced intestinal permeability and inflammation in conditions such as Crohn’s disease and ulcerative colitis.
Short bowel syndrome
Where L-glutamine has demonstrated improved nutrient absorption and reduced dependence on parenteral nutrition.
Immune and metabolic support
Reflecting glutamine’s central role as a fuel source for rapidly dividing cells and immune function.
These findings underscore the importance of grade, purity, and formulation in achieving therapeutic benefit—reinforcing the need for pharmaceutical-quality manufacturing.
